Karolinska Developments portföljbolag Umecrine Cognition säkrar SEK 23,8 miljoner för den fortsatta kliniska utvecklingen av golexanolon
December 19, 2024 02:50 ET
|
Karolinska Development AB (publ)
STOCKHOLM, SVERIGE, 19 december 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget Umecrine Cognition har genomfört en kapitalanskaffning om SEK 23,8 miljoner genom...
Karolinska Development’s portfolio company Umecrine Cognition raises MSEK 23.8 to continue clinical development of golexanolone
December 19, 2024 02:50 ET
|
Karolinska Development AB (publ)
STOCKHOLM, SWEDEN – December 19, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that the portfolio company Umecrine Cognition has raised SEK 23.8 million through a...
Karolinska Developments styrelse utser Ben Toogood till ny ordförande
December 18, 2024 10:30 ET
|
Karolinska Development AB (publ)
STOCKHOLM, 18 december 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att bolagets styrelse utsett ledamoten Ben Toogood till ny styrelseordförande fram till nästa bolagsstämma. ...
Karolinska Development’s Board of Directors appoints Ben Toogood as new Chairman
December 18, 2024 10:30 ET
|
Karolinska Development AB (publ)
STOCKHOLM, SWEDEN – December 18, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that the company’s Board of Directors has appointed Ben Toogood as new Chairman until the next...
Karolinska Developments styrelseordförande avgår på egen begäran
December 11, 2024 05:45 ET
|
Karolinska Development AB (publ)
STOCKHOLM, 11 december 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att bolagets styrelseordförande, professor Hans Wigzell, idag lämnar sin position på egen begäran. Styrelsen...
Karolinska Development’s Chairman of the Board resigns at his own request
December 11, 2024 05:45 ET
|
Karolinska Development AB (publ)
STOCKHOLM, SWEDEN – December 11, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that the company’s Chairman of the Board, Professor Hans Wigzell, has decided to resign from...
Karolinska Development avyttrar 4,6 miljoner aktier i portföljbolaget OssDsign
December 10, 2024 15:54 ET
|
Karolinska Development AB (publ)
STOCKHOLM, SVERIGE 10 december 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) avyttrar 4,6 miljoner aktier i portföljbolaget OssDsign och stärker därmed investmentbolagets likviditet. Efter...
Karolinska Development divests 4,6 million shares in portfolio company OssDsign
December 10, 2024 15:54 ET
|
Karolinska Development AB (publ)
STOCKHOLM, SWEDEN, December 10, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) divests 4,6 million shares in the portfolio company OssDsign and thereby strengthens the investment company’s...
Karolinska Developments portföljbolag Modus Therapeutics initierar en fas 2-studie med sevuparin för behandling av kronisk njursjukdom med anemi
December 09, 2024 08:03 ET
|
Karolinska Development AB (publ)
STOCKHOLM, SVERIGE, 9 december 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Modus Therapeutics har doserat den första patienten i en klinisk fas 2-studie...
Karolinska Development's portfolio company Modus Therapeutics initiates a phase 2 study with sevuparin for treatment of chronic kidney disease with anemia
December 09, 2024 08:03 ET
|
Karolinska Development AB (publ)
STOCKHOLM, SWEDEN – December 9, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has dosed the first patient in a phase 2...